Thu.May 30, 2024

article thumbnail

FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea

Pharmaceutical Technology

The US FDA approved Teva Pharmaceuticals’ AUSTEDO XR as a once-daily treatment option for tardive dyskinesia and Huntington’s disease chorea.

article thumbnail

CinCor’s ‘hub-and-spoke’ parent nabs new funding to build its next biotechs

Bio Pharma Dive

The $73 million round for CinRx Pharma, which created a startup AstraZeneca bought last year, will help fund subsidiaries making drugs for obesity, irritable bowel syndrome and gastroparesis.

Drugs 177
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DoP launches portal and constitutes ICPMR for implementation of R&D policy

AuroBlog - Aurous Healthcare Clinical Trials blog

The Department of Pharmaceuticals (DoP) has said that it has developed a portal for monitoring the implementation of the research and development (R&D) policy and has constituted the Indian Council for Pharmaceuticals and Medtech Research and Development (ICPMR), as envisaged in the National Policy on Research and Development and Innovation in the Pharma-Medtech Sector in […]

Research 174
article thumbnail

Immunovant changes up plans for closely watched autoimmune drugs

Bio Pharma Dive

The company is prioritizing development of an earlier so-called FcRn inhibitor, a type of medicine that’s shown promise treating multiple inflammatory conditions.

Medicine 171
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

BioNTech and CEPI expand deal to boost Africa’s vaccine capabilities

Pharmaceutical Technology

BioNTech and CEPI have announced an expansion of their strategic partnership, aiming to strengthen the mRNA vaccine ecosystem in Africa.

article thumbnail

Otsuka defies digital health downturn with new company

Bio Pharma Dive

With “no playbook out there” to fall back on, the new company is taking a long-term approach as it develops its portfolio, an Otsuka Precision Health exec told MedTech Dive.

More Trending

article thumbnail

AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs

Pharmaceutical Technology

In May 2024, Italy’s medicines agency AIFA published a strategic overview, detailing all new active substances that are potentially advancing towards EU marketing authorisation.

Medicine 130
article thumbnail

May 30, 2024: Workshop Materials Now Available From ‘Patient-Centered Research in Real-World Settings: Essentials of Embedded Pragmatic Clinical Trials’

Rethinking Clinical Trials

Complete materials are now available from the NIH Pragmatic Trials Collaboratory’s recent workshop, “Patient-Centered Research in Real-World Settings: Essentials of Embedded Pragmatic Clinical Trials.” The 1-day workshop, held on May 19 at the 45th annual Society for Clinical Trials meeting in Boston, introduced concepts in the design, conduct, and implementation of pragmatic clinical trials embedded in healthcare systems.

article thumbnail

Gilead urged to improve access to HIV drug by public figures and celebrities

Pharmaceutical Technology

Several personalities, including a Nobel-winning scientist who helped discover HIV, have written to Gilead in an open letter about fairer access to Sunlenca.

Scientist 130
article thumbnail

Interview: Has Cybin hit the biggest breakthrough in 40 years to treat psychiatric disorders?

Outsourcing Pharma

In an intriguing interview with Cybinâs CEO, Doug Drysdale, OSP senior editor, Liza Laws found out how second-generation psychedelics could be the biggest breakthrough in psychiatry in 40 years.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

How cell and gene therapy are evolving

Pharmaceutical Technology

The cell and gene therapy market is accelerating in its evolution, as well as commercial approvals, with new therapeutic options for patients

article thumbnail

BioNTech, flush with $145M from CEPI, looks to expand mRNA vaccine production in Africa

Fierce Pharma

As various efforts to produce next-generation vaccines in Africa are being carried forward by the likes of the World Health Organization (WHO) and the Bill & Melinda Gates Foundation, BioNTech | Under an expansion of the partners’ existing deal, the Coalition for Epidemic Preparedness Innovations (CEPI) is committing up to $145 million to bolster BioNTech’s efforts to establish vaccine R&D and manufacturing capabilities at the German company’s facility in Kigali, Rwanda.

article thumbnail

BIOSECURE “grandfather” amendment softens impact of US-China trade ban

Pharmaceutical Technology

The US BIOSECURE bill aims to prevent US companies from working with Chinese biotechs, but is softened with a "grandfather" clause.

130
130
article thumbnail

COVID-19 vaccinations now ‘alarmingly low’ in Europe

pharmaphorum

COVID-19 vaccination rates have fallen precipitously in Europe and should be ramped up this autumn so they are at least in line with influenza vaccine uptake.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

EC grants orphan medicinal product status to Rocket’s RP-A601

Pharmaceutical Technology

The EC has granted orphan medicinal product designation for Rocket Pharmaceuticals’ RP-A601 for PKP-2 related arrhythmogenic cardiomyopathy.

Medicine 130
article thumbnail

Short reads, big impact: How genomics is revolutionising cancer research

pharmaphorum

Discover how genomics is transforming cancer research through the study of DNA, RNA, and ctDNA. Learn about the latest breakthroughs in the field in this insightful short read.

Genome 121
article thumbnail

Untapped opportunities: Fulfilling the promise of decentralized clinical trials

Pharmaceutical Technology

Decentralized clinical trials are driving new complexities in data collection. The right solutions provider can make all the difference.

article thumbnail

Who decides whether you get into a clinical trial?

Antidote

One may choose to participate in a clinical trial for many reasons. Volunteering often has multiple benefits, from advancing medical research to gaining access to cutting-edge medical care. However, deciding to enroll in a clinical trial is only one part of the process.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Untapped opportunities: Fulfilling the promise of decentralized clinical trials

Pharmaceutical Technology

Decentralized clinical trials are driving new complexities in data collection. The right solutions provider can make all the difference.

article thumbnail

CSL Seqirus scores 4th award from US government for bird flu pandemic preparedness

Fierce Pharma

The United States Department of Health and Human Services has expanded its avian flu pandemic preparedness partnership with CSL Seqirus, lining up the vaccine specialist to

article thumbnail

Sanofi completes the $1.7bn acquisition of Inhibrx

Pharmaceutical Technology

With the completed acquisition, Sanofi will gain access to SAR447537, Inhibrx’s human recombinant protein in development for AATD.

Protein 130
article thumbnail

Gilead's Trodelvy suffers double whammy as failed bladder cancer trial raises flag over early deaths

Fierce Pharma

In the span of half a year, Gilead Sciences' Trodelvy has flopped a second phase 3 trial. | Following a high-profile lung cancer setback in January, Gilead said Thursday that Trodelvy also failed to move the needle in a bladder cancer study. The flop threatens the ADC's accelerated approval in the tumor type.

Trials 113
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Agios sells vorasidenib US royalties for $905m

Pharmaceutical Technology

Royalty Pharma will receive 15% on US sales of vorasidenib, up to $1bn, and at a 12% rate beyond that.

Sales 147
article thumbnail

Bristol Myers secures another FDA go-ahead for Breyanzi, this time in mantle cell lymphoma

Fierce Pharma

In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach of its cell therapy. | In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach of its cell therapy. For the third time in as many months, those efforts have yielded a label expansion at the FDA.

article thumbnail

Ikena further sheds staff and pipeline in bid to maximise value

Pharmaceutical Technology

The company has fired 53% of its workforce and is shutting down the development of a Phase I pipeline candidate.

article thumbnail

Verona's ensifentrine will be a 'paradigm shift in COPD treatment,' GlobalData says

Fierce Pharma

With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much attention as it is on the verge of becoming the first biologic to treat c | With Verona Pharmaceuticals' COPD candidate ensifentrine approaching its FDA decision date, GlobalData has referred to it as a “paradigm shift in COPD treatment.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Merck agrees to acquire EyeBio for up to $3bn

Pharmaceutical Technology

Merck has announced a definitive agreement to acquire EyeBio, through a subsidiary, for a total of up to $3bn.

130
130
article thumbnail

Safeguarding Patients: A Day in the Life of a Pharmacovigilance Leader

XTalks

Pharmacovigilance, particularly within cancer therapeutics, is more than just a profession for Ashish Jain, Senior Director of Clinical Safety and Pharmacovigilance at Curis. Driven by a deep-rooted passion for patient safety, Ashish provides a personal glimpse into his everyday responsibilities and the evolving landscape of his field. From Pharmacy School to Pharmacovigilance Ashish’s journey into pharmacovigilance began during his pharmacy school days, where an internship first exposed him to

article thumbnail

MSD agrees to acquire EyeBio for up to $3bn

Pharmaceutical Technology

MSD has announced a definitive agreement to acquire EyeBio, through a subsidiary, for a total of up to $3bn.

130
130
article thumbnail

US Congress passes bill to end Parkinson’s disease

pharmaphorum

The US Congress has passed the first-ever federal bill dedicated to ending Parkinson’s disease, modelled on similar legislation for Alzheimer’s enacted in 2011

111
111
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.